Clinical Trials Logo

Clinical Trial Summary

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly among patients undergoing identical therapy but experiencing different outcomes. The proposed observational study builds upon these hypotheses by proposing a large cohort design to further assess the associations between the gut microbiota (composition and function), host immune system, and ICI treatment efficacy across multiple cancer types.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05037825
Study type Observational
Source VastBiome
Contact Hanane Arib, MS
Phone 650-479-5539
Email [email protected]
Status Not yet recruiting
Start date September 14, 2021
Completion date September 14, 2028

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Active, not recruiting NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Active, not recruiting NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05024214 - Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04955743 - Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Phase 2
Not yet recruiting NCT05013099 - Study of 89Zr-Df-crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies Phase 2
Not yet recruiting NCT04535687 - Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
Withdrawn NCT02307474 - A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer N/A
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Terminated NCT01482949 - A Rollover Protocol for Subjects Previously Treated With AGS-003 Phase 2
Completed NCT01283048 - Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma Phase 1
Completed NCT01420601 - Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)